Phase 2 confirmatory study of cemiplimab (350 mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6. J of Skin [Internet]. 2023 Mar. 13 [cited 2025 Apr. 19];7(2):s175. Available from: https://skin.dermsquared.com/skin/article/view/1999